← Leaderboards
Raquel L Lieberman
Brigham And Women'S Hospital
$8,076,393
Attributed
$9,096,852
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,096,852 · 6
By mechanism
R01$8,171,568 · 3
R21$831,829 · 2
F32$93,455 · 1
Top collaborators
- Jennifer A Maynard4 shared
- Brian S J Blagg2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Michael S Wolfe$15,472,448
- Tracy L Young-Pearse$25,012,544
- Dennis J Selkoe$33,298,694
- Malcolm A Leissring$5,920,046
- Tomas Maira-Litran$1,043,055
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightStructureMolecularCellsMutationMutantFunctional DisorderMyocilinRetinaGlaucomaCell DeathBlindnessPhysiologic Intraocular PressureTrabecular Meshwork StructureProteinsEarly OnsetLeadEndoplasmic ReticulumEye DiseasesOlfactomedinInheritedAmyloidNerve DegenerationMolecular Chaperones
Grant awards (33)
Selective Inhibition of GRP 94 to Treat Ocular Hypertension and Glaucoma$591,767
R01 · FY2025 · EY
Characterization of purified myocilin: glaucoma as a protein misfolding disease$400,952
R01 · FY2025 · EY · contact PI
Molecular determinants of cytotoxicity due to mutant myocilin misfolding$337,162
R01 · FY2025 · EY · contact PI
Selective Inhibition of GRP 94 to Treat Ocular Hypertension and Glaucoma$617,323
R01 · FY2024 · EY
Molecular determinants of cytotoxicity due to mutant myocilin misfolding$447,479
R01 · FY2024 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$400,952
R01 · FY2024 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$400,952
R01 · FY2023 · EY · contact PI
Characterization of purified myocilin : glaucoma as a protein misfolding disease DEIA Supplement$384,626
R01 · FY2023 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$99,683
R01 · FY2023 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$76,702
R01 · FY2023 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$388,923
R01 · FY2022 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$99,683
R01 · FY2022 · EY · contact PI
CHARACTERIZATION OF PURIFIED MYOCILIN: INSIGHT INTO GLAUCOMA$76,702
R01 · FY2022 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$440,499
R01 · FY2021 · EY · contact PI
Recombinant antibodies to differentiate among the many conformations of glaucoma-associated myocilin$223,016
R21 · FY2021 · EY
Request for Supplement to Promote Diversity in Health Related Research$99,683
R01 · FY2021 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$374,985
R01 · FY2020 · EY · contact PI
Recombinant antibodies to differentiate among the many conformations of glaucoma-associated myocilin$205,237
R21 · FY2020 · EY
Characterization of purified myocilin: glaucoma as a protein misfolding disease$101,369
R01 · FY2020 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$490,779
R01 · FY2019 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$377,769
R01 · FY2018 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$114,348
R01 · FY2018 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$355,401
R01 · FY2017 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$290,730
R01 · FY2015 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$290,731
R01 · FY2014 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$277,712
R01 · FY2013 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$292,328
R01 · FY2012 · EY · contact PI
Characterization of purified myocilin: glaucoma as a protein misfolding disease$342,328
R01 · FY2011 · EY · contact PI
Crystal structure of signal peptide peptidase with engineered antibody fragment$213,061
R21 · FY2011 · DK · contact PI
Crystal structure of signal peptide peptidase with engineered antibody fragment$190,515
R21 · FY2010 · DK · contact PI
Structure of signal peptide peptidase$3,483
F32 · FY2008 · AG · contact PI
Structure of signal peptide peptidase$45,976
F32 · FY2007 · AG · contact PI
Structure of signal peptide peptidase$43,996
F32 · FY2006 · AG · contact PI